PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Radioisotopes”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 19 recordsLinked to original sources
PubMed2005

Comparison of radioisotope methods and a non-radioisotope method to measure platelet survival in the baboon.

BACKGROUND: The in vivo survival of autologous fresh and preserved platelets can be measured using 51-Cr and 111-In-oxine radioisotope procedures and by a non-radioisotope procedure using biotin-X-N-hydroxysuccinimide (NHS) with detection in the flow cytometer using fluorescent streptavidin. This study was done to assess the specificity of the radioisotopes 51-Cr and 111-In-oxine and non-radioactive biotin-X-NHS to label platelets to measure their in vivo recovery and lifespan. STUDY DESIGN AND METHODS: In the study reported here, aliquots of autologous platelets from the same baboon were labeled with 51-Cr, 111-In oxine and biotin-X-NHS to measure platelet survival. Both cell-associated and platelet-associated 51-Cr and 111-In oxine radioactivity were assessed to measure the in vivo recovery and lifespan of platelets. Blood volume was measured using the 125I albumin plasma volume and the total body hematocrit. RESULTS: In vivo recovery values measured during the 1-3h post-infusion period and during the 8 day post-infusion period showed significant differences between the 51-Cr-labeled and the 111-In-oxine labeled platelets. In the 51-Cr-labeled platelets, the cell-associated radioactivity was about 50% higher than the platelet-associated radioactivity. In the 111-In-oxine labeled platelets, the cell-associated radioactivity was about 10% higher than the platelet-associated radioactivity. Similar in vivo recovery values were observed in the biotin-X-NHS labeled platelets and the 111-In-oxine labeled platelets assessed from the cell-associated 111-In-radioactivity. CONCLUSION: The radioisotope 51-Cr and 111-In are non-specific labels for platelets, whereas biotin-X-NHS is a specific label for platelets identified in the flow cytometer with fluorescent streptavidin. The in vivo recovery values of autologous baboon platelets were similar when assessed from the cell-associated 111-In-oxine radioactivity and biotin-X-NHS labeled platelets.

Animals↗
PubMed1977

[Remote system for the mass production of short-lived radioisotopes in a cyclotron. Development of the system and radioisotope production].

A system was developed for producing short-lived radioactive substances (11CO, 11CO2, 13NN, 13NH3, 18F-, 62Zn2+, 123I-, etc.) on a scale enough for clinical use, which could also be used for analyzing them rapidly and for investigating their production methods, with less received dose by workers. The system enabled us to produce remotely several tens mCi of of short-lived radioactive susbtances readily usable for clinical diagnosis, continuosly for radioactive gases, 11CO, 11CO2 and 13NN, or repeatedly at short intervals for radioactive aqueous solutions of 13NH3, 18F-, etc. Employing this system, the average received dose per month was reduced considerably.

Carbon Radioisotopes↗
PubMed2004

Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes.

BACKGROUND: Sentinel lymph node (SLN) mapping and biopsy have emerged as the technique of choice for axillary staging of breast cancer. Several methods have been developed to identify SLNs, including peritumoral or intradermal injection of isosulfan blue dye or technetium sulfur colloid (TSC). We hypothesize that intradermal TSC is the optimal mapping technique and can be used alone to identify SLNs. STUDY DESIGN: From March 1997 through January 2001, 180 women with T1 and T2 invasive breast cancer and clinically negative axilla underwent SLN mapping and biopsy. Peritumoral TSC was injected in 74 patients, 62 of whom also received peritumoral blue dye. Intradermal TSC (above tumor) was performed in 94 patients, 76 of whom also received peritumoral blue dye. Technetium-rich nodes were identified intraoperatively using a hand-held gamma probe and blue nodes were identified visually. Hematoxylin- and eosin-stained SLN sections were examined by light microscopy for breast cancer metastases. RESULTS: Overall, the SLN mapping procedures were successful in 91% of patients. Peritumoral and intradermal TSC were successful in identifying SLNs in 78% and 97% of patients, respectively. Peritumorally injected isosulfan blue was successful in identifying 83% of SLNs. Intradermal TSC was found to be superior to peritumoral TSC and peritumoral blue dye in identifying SLNs (p = 0.00094, chi-squared, and p = 0.020, ANOVA). CONCLUSIONS: SLN mapping by intradermal TSC has a significantly higher success rate than peritumoral TSC or blue dye. There was minimal benefit in identifying additional SLNs with addition of peritumoral blue dye to intradermal TSC. So, SLN mapping and biopsy using intradermal-injected TSC can be used alone to effectively stage the axilla for breast cancer.

Breast Neoplasms↗